NEW YORK (Reuters Health) Oct 18 –
Bristol-Myers Squibb Co.’s antibiotic Tequin (gatifloxacin) has received an additional US approval as a treatment for uncomplicated skin and skin structure infections, the US Food and Drug Administration (FDA) said on Friday.
Tequin was first approved in the US in December 1999 as a treatment for respiratory infections, and has been subsequently cleared for other indications including urinary tract infections and gonorrhea.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!